Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 16, 2017 – The FDA approved a new warning to the Tysabri (natalizumab) drug label regarding acute retinal necrosis (ARN).
Download PDF
Return to publications